Dr Constantine Alifrangis is a Consultant Medical Oncologist based in London, specialising in the treatment of urological cancers, including prostate, bladder, testicular, and penile cancer. He graduated from Guys' Kings and St Thomas' Medical School, where he was awarded the University Gold Medal for medicine. He completed his postgraduate medical training in oncology at Imperial College London and conducted advanced prostate cancer research at Hammersmith Hospital. His work earned him a Wellcome Trust fellowship to explore the link between cancer genetics and the efficacy of novel therapies, culminating in a PhD from the University of Cambridge in 2014. He was also honoured with the Sylvia Lawler prize by the Oncology section of the Royal Society of Medicine.

In 2016, Dr Alifrangis was appointed Consultant Medical Oncologist at University College London Hospital and St Bartholomew's. He serves as the Lead Oncologist for Testicular Cancer and treats patients with advanced prostate cancer. Additionally, he is part of a specialist team dedicated to the care of patients with penile cancer.

Dr Alifrangis is deeply involved in research focused on the genetic basis of cancer and drug resistance, advocating for personalised approaches to cancer treatment. He is the Lead Investigator for several clinical studies on rarer and understudied cancers. His research has been presented at numerous international conferences and published in esteemed cancer journals, including the Lancet, Journal of Clinical Oncology, and Clinical Cancer Research.

Dr Alifrangis's areas of expertise include chemotherapy and the treatment of bladder cancer, genito-urinary cancer, penile cancer, prostate cancer, and testicular cancer. His commitment to advancing cancer treatment and his extensive research contributions make him a leading figure in the field of medical oncology.